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Available online 8 October 2011Abstract Successful use of stem cell-based therapeutic products is conditioned by transplantation of optimized cells in per-
missive microenvironment. Mesenchymal stem cell (MSC) fates are tightly regulated by humoral factors, cellular interactions
and extracellular matrix (ECM) components, such as glycosaminoglycans (GAG), which are complex polysaccharides with struc-
tural heterogeneity. During osteogenesis, a temporally controlled expression of particular GAG species is required to interact
with specific growth promoting and differentiating factors to regulate their biological activities. As a comparative tool to study
natural GAG, we used structurally and functionally related synthetic GAG mimetics. One of these compounds [OTR4120] was
previously shown to stimulate bone repair in rat models. Here, we demonstrate that structurally distinct GAG mimetics stim-
ulate differentially clonogenicity, proliferation, migration and osteogenic phenotype of MSC in vitro, according to their specif-
ic chemical signature, underlying the role of sulfate and acetyl groups in specific interactions with heparin binding factors
(HBF). These effects are dependent on FGF-2 interactions since they are inhibited by a FGF receptor 1 signaling pathway
blocker. These data suggest that the in vivo [OTR4120] bone regenerative effect could be due to its ability to induce MSC migra-
tion and osteogenic differentiation. To conclude, we provide evidences showing that GAG mimetics may have great interest for
bone regeneration therapy and represent an alternative to exogenous growth factor treatments to optimize potential thera-
peutic properties of MSC.
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Mesenchymal stem cells (MSC) have a number of potential
therapeutic applications for tissue regeneration, due to
their ability to differentiate into various lineages. Studies
of their mechanism of action have suggested that MSC trans-
plants are short-lived in vivo and that their therapeutic
properties are largely related to paracrine interactions
with endogenous tissue and host immune cells, through the
release of soluble mediators that elicit the biological re-
sponse. The osteogenic potential of MSC is currently largely
exploited in bone regeneration applications, since their im-
munomodulatory capacities were thought to be profitable
in therapy against graft-versus-host disease. However, such
therapeutic applications of MSC products have demonstrated
their limited efficacy in bone formation. Thus new tissue en-
gineering strategies are currently being developed based on
the association of humoral growth factors and scaffolds, able
to mimic proper extracellular matrix (ECM) microenviron-
ment, in which therapeutic MSC are expected to survive,
proliferate and differentiate more efficiently.
Sulfated glycosaminoglycans (GAG) are major ECM com-
ponents. GAG have not only structural but also functional
roles since they participate in the regulation of biological
processes such as cell growth, migration and differentiation.
The structure of GAG is highly complex because of the great
heterogeneity in the degree of substitution and the variable
positioning of their sulfate and acetyl groups. Such variabil-
ity affects the intra-molecular repartition of ionic charges
and hydrophobic/hydrophilic regions and also their interac-
tions with surrounding molecules. Heparan sulfates (HS)
are the GAG family members with the highest structural
complexity. The presence of spatially discrete sulfated do-
mains in HS structures is a unique feature conferring specific
physicochemical and biological properties to these sugars. It
is now accepted that particular structural characteristics
may allow GAG to modulate the activities of numerous regu-
latory factors like heparin binding proteins' (HBP), which in-
clude growth factors, chemokines, cytokines and enzymes,
(for review, Gallagher, 2006). GAG thus provide matrix-
bound or cell surface-bound reservoirs for HBP, protecting
them from proteolytic degradation and increasing their
half-life. Because of their ability to stabilize growth factors,
GAG act as modulators of their bioavailability (for review,
Handel et al., 2005) and thus as initiators of HBP signaling
(Friedl et al., 1997).
Osteogenesis is a carefully orchestrated series of events that
requires a timely regulated expression of growth promoting and
osteogenic differentiation factors, but also of GAG. The basic
fibroblast growth factor (FGF-2) is a HBP produced by osteo-
blasts and stored in the bone ECM, from where it can modulate
bonemarrow stromal cells and osteoblast proliferation through
autocrine/paracrine mechanisms (Jackson et al., 2006). In vivo
studies have demonstrated the significant effect of FGF-2 on
bone formation (Montero et al., 2000), whereas the complexity
of itsmitogenic activity has been pointed out in in vitro studies:
FGF-2 has stimulatory (Ling et al., 2006; Pitaru et al., 1993) or
inhibitory (Hanada et al., 1997; Dombrowski et al., 2009) ef-
fects on osteogenic differentiation of mesenchymal cells
depending on dose and duration of treatments. Since it is well
known that distinct functional GAG are produced along the os-
teoblast differentiation process (Nurcombe et al., 2007), it ishypothesized that GAG structural changes could then be impli-
cated on differential FGF-2 regulations. Accordingly, increased
levels of key enzymes involved in GAG biosynthesis were corre-
lated with ECM mineralization during osteogenic differentia-
tion of MSC (Muller et al., 2008), whereas inhibition of GAG
synthesis blocked the mitogenic effect of FGF-2 on osteoblasts
(Molteni et al., 1999). FGF-2 activity on cell growth and differ-
entiation were positively or negatively regulated by specific
heparin saccharides (Ostrovsky et al., 2002; Goodger et al.,
2008) and particular HS saccharides have shown an inhibitory
effect on osteogenesis through inhibition of FGF-2 activity
(Guimond and Turnbull, 1999). The effects of both FGF-2 and
HS on rat MSC proliferation and differentiation are mediated
through FGF receptor 1 (FGFR1) (Dombrowski et al., 2009).
Moreover, structural signatures of HS have also been implicat-
ed in the regulation of the biological activity of other osteo-
genic factors such as bone morphogenic protein (BMP)
(Manton et al., 2007).
Since GAG effects are potentially related to their abilities
to modulate osteogenic factor activities, more information
on their chemical structure is still required for a better under-
standing of these complex processes. A family of sulfated poly-
saccharides, structural and functional analogs of natural GAG,
has been developed as a new approach to integrate the rele-
vance of the chemical signatures of GAG to their biological
function. The interest of such GAGmimetics is that their struc-
tures can be modulated by chemical synthesis, allowing avail-
ability of well-characterized products with high therapeutic
potential (Papy-Garcia et al., 2005). These compounds, also
named RGTA (for ReGeneraTing Agents), improved both the
efficiency and quality of wound healing after local treatment
in numerous animal models of injury, such as skin (Garcia-
Filipe et al., 2007), muscle (Meddahi et al., 2002) and bone re-
pair (Escartin et al., 2003; Lafont et al., 2004). Their regener-
ative properties could be partly explained by their interactions
with HBP (Meddahi et al., 1996; Desgranges et al., 1997). Some
studies on this family of compounds have shown that they are
more stable than natural GAG because they resist glycanase
activities (Meddahi et al., 2002). This property enhances
their ability to stabilize and protect HBP from enzymatic deg-
radations in vitro, increasing their half-life and improving
their biological effects, as compared to endogenous GAG
(Rouet et al., 2005; Garcia-Filipe et al., 2007). In particular,
a GAG mimetic induced closure and repair in a model of tre-
phine skull defect in rats in which no spontaneous healing oc-
curred (Lafont et al., 1998). This molecule also accelerated
the spontaneous healing process observed in rat craniotomy
defects (Colombier et al., 1999). In vitro investigations demon-
strated that themimetic, used alone or associated with FGF-2,
stimulated the expression of osteoblast markers such as alka-
line phosphatase without modifying the proliferation of
MC3T3-E1 osteoblastic cells derived from mouse calvarias
(Blanquaert et al., 1999). Moreover a kinetic study of the
early regenerative effects of the mimetic during skull suture
indicated that the treatment could have elicited a favorable
microenvironment promoting the commitment of dura mater
cells which are the primary source of osteoprogenitors (Lafont
et al., 2004).
To explain this effect of GAG mimetics on bone regenera-
tion, we hypothesize that it is partly due to their capacity to
modulate endogenous MSC properties in vivo. Therefore, to
validate this hypothesis we investigated in this study whether
182 G. Frescaline et al.some particular mimetics are able to potentiate effectively
the properties of rat MSC (rMSC) in vitro. Two different mi-
metics with specific structural signatures, [OTR4120] and
[OTR4131], were compared to natural GAG on their ability to
modulate clonogenicity, growth, migration and osteogenic
differentiation of rMSC. Each GAG mimetic was used in rMSC
culture, alone or in combination with a long term treatment
with FGF-2, to assess the advantages of a GAG mimetic condi-
tioning prior to therapeutic treatment of bone defect by MSC.Results
Effects of GAG and FGF-2 on colony forming efficiency
of rat MSC
Colony forming efficiency (CFE) of rMSC was evaluated from
bone marrow mononucleated cells (BMMC) cultured in medi-
um supplemented or not with GAG mimetics, [OTR4131] or
[OTR4120], or heparin or FGF-2 for 10 days (Fig. 1). Exposure
of cells to GAG mimetics or to heparin induced an increase of
the CFE as compared to untreated cells (CT). Although some
inter-individual variability in the intensity was observed, this
effect was significant for the mimetic [OTR4120], with a 3
fold increase (pb0.05). Surprisingly, exposure to FGF-2 de-
creased by half the CFE of BMMC (pb0.05). For further ex-
periments, rMSC expanded in the absence or presence of
FGF-2 were respectively named rMSC(−) and rMSC(+) and
used for testing GAG mimetic effects on MSC properties.
In order to characterize rMSC populations obtained in these
culture conditions, cell surface antigen expressions were ana-
lyzed by flow cytometry from the initial BMMC whole fraction
to the amplification steps, during passage 1 and 2 (P1 and P2)A
Figure 1 Effect of GAG mimetic, Heparin and FGF-2 treat-
ment on rMSC clonogenicity. Colony Forming Efficiency (CFE)
of rat MSC were evaluated as the number of CFU-F at day 10
per 106 BMMC seeded, without (CT) or with GAG mimetics
[OTR4131] and [OTR4120] (100 ng/ml), Heparin (100 ng/ml) and
FGF-2 (5 ng/mL). Each CFE is the mean of the value obtained
for at least 3 wells of 6-well plates per condition and per rat
sample. Experiments were performed on N=6 independent
animals.(Table 1). In the absence of FGF-2, mesenchymal marker ex-
pressions, including CD44, CD54, CD73 and CD90, increased
during the subculture and were highly expressed (90% to 99%)
at P2. During this rMSC(−) subculture, the percentage of cells
expressing hematopoietic markers, such as leukocyte CD45
and macrophage CD11b, decreased progressively, from 59%
and 55% of the BMMC at day 0 respectively to 7% and 10% at
P2, corresponding to elimination of non adherent hematopoi-
etic cells from the culture. In the presence of FGF-2, CD44
and CD54 expressions were always highly expressed (98% and
95% respectively), while lower percentage of cells expressed
CD73 and CD90 (72% and 62% respectively) at P2, and percent-
ages of positive cells for the two hematopoietic markers still
high (35% and 28% respectively). CD31 expression was initially
low on BMMC at day 0 and decreased with subculturing inde-
pendently of FGF-2, suggesting that endothelial cells disap-
peared gradually from the culture. These data indicate that
subcultures of rat BMMC performed in the absence of FGF-2
resulted in a cell population enriched in mesenchymal progen-
itor cells. In the presence of FGF-2 the CFE was decreased and
contaminating cells are present, despite homogeneous mor-
phology and clear expression of mesenchymal markers.Effects of GAG and FGF-2 on rMSC growth
Effects of mimetics or natural GAG on the growth of the
rMSC(−) and rMSC(+) populations were tested in 2% FCS
(Fetal Calf Serum) medium for 72 h (Fig. 2). In the absence
of FGF-2 long term treatment (Fig. 2A), HS and heparin had
significant effects on the growth of rMSC(−) with maximal in-
creases of 1.5-fold and 1.6-fold respectively for the
100 ng/mL dose. Similar growth effect on rMSC(−) was only
observed with addition of the acetylated and sulfated GAG
mimetic [OTR4131] (1.25-fold increase with 100 ng/mL
dose) whereas no significant effect was observed with the
sulfated analog [OTR4120] (non acetylated compound). As a
positive control, a 2 fold increase of rMSC(−) growth was
obtained in the presence of FGF-2. Since HS is a co-
receptor for the FGF/FGFR complex and because FGFR1 is
a high affinity receptor for FGF-2 binding, the same experi-
ments were performed in the presence of SU5402, the chem-
ical inhibitor SU5402 of FGF-R1 signaling. Addition of this
blocker was effective since we noted an inhibition of cell
growth induced not only by FGF-2 but also by natural GAG
and by the mimetic [OTR4131] as well. These results indicate
that the effect of active GAG are partly mediated through
the FGF-2/FGFR1 pathway and could be due to interaction
with endogenous FGF-2, present in FCS or secreted by rMSC.
When rMSC were amplified with FGF-2 long term treat-
ment (Fig. 2B), we observed that the growth rate of CT
rMSC(+) (dotted line) decreased by about 25% as compared
to CT rMSC(−) (solid line, Fig. 2A). In the presence of FGF-
2, HS (100 ng/mL) and heparin (10 ng/mL) potentiated
rMSC(+) growth by 1.3 fold and 1.7 fold increases, respec-
tively. Addition of acetylated GAG mimetic [OTR4131]
showed a higher effect than that observed on rMSC(−),
with a 1.5 fold increase at 100 ng/mL. As observed with
rMSC(−) the non acetylated GAG mimetic [OTR4120] had no
significant effect. Finally, addition of SU5402 decreased
the proliferative effects of the natural GAG, the mimetic
[OTR4131], and the FGF-2 on rMSC(+).
Table 1 Phenotypic analysis of surface markers expressed by mesenchymal progenitor cells amplified without or with FGF-2.
Antigen D0 (BMMC) FGF2 P0 (CFU-F) P1 P2
CD31 8%+/−2 – 1.9%+/−0.2 0.8%+/−0.2 0%+/− 0
+ 2.2%+/−0.2 0.7%+/−0.2 0.3%+/−0.1
CD45 59%+/−8 – 18%+/−2 22%+/−2 7%+/−3
+ 33%+/−3 38%+/−3 35%+/−4
CD11b 55%+/−4 – 23%+/−3 18%+/−3 10%+/−2
+ 19%+/−3 30%+/−3 28%+/−5
CD44 57%+/−13 – 99%+/−1 96%+/−2 99%+/−1
+ 98%+/−1 98%+/−1 98%+/−1
CD54 18%+/−2 – 99%+/−1 99%+/−1 99%+/−1
+ 92%+/−2 95%+/−2 95%+/−2
CD73 10%+/−1 – 86%+/−2 86%+/−2 90%+/−2
+ 69%+/−2 65%+/−2 72%+/−2
CD90 34%+/−4 – 81%+/−2 81%+/−2 94%+/−2
+ 58%+/−2 51%+/−2 62%+/−2
Flow cytometry analysis were performed on endothelial (CD31), hematopoietic (CD45, CD11b) and mesenchymal (CD44, CD54, CD73 and CD90)
markers expressed on BMMCat day 0 (D0) and all along amplification step (passages P0, P1 and P2) of rMSC treated (+) or not (–) with FGF-2. Results
were expressed as percentage of positive cells from populations, and correspond to the mean and SEM from N=4 independent experiments.
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pound [OTR4120] had no effect, the addition of acetyl groups
to its counterpart [OTR4131] was able to significantly modify
its ability to potentiate the growth of rMSC to a similar extent
than HS or heparin. This effectmay occur through interactions
with HBP, including FGF-2, present at low concentration (in 2%
FCS) or endogenously expressed by rMSC.
Effects of FGF-2 and GAG on rMSC migration
Chemoattractant potential of the two GAG mimetics was
tested on rMSC(−) (Fig. 3A) and rMSC(+) (Fig. 3B) in an in
vitro Boyden chambers migration model.
Basal migration levels of cells in control conditions (CT)
were first analyzed in the absence of serum (FCS-0%) show-
ing that rMCS(−) were less able to migrate as compared to
rMSC(+). This suggests that FGF-2 long term treatment po-
tentiate migration properties of rMSC. In the presence of
FCS-2%, basal migration levels of cells (CT) were increased
as compared to FCS-0%, and were roughly the same for
rMSC(−) and rMSC(+), indicating that in the presence of
serum, FGF-2 effect on rMSC migration is negligible. This
was confirmed by the addition of SU5402 that induced only
a slight decrease of migration in these CT conditions.
The effects of GAG mimetics were then analyzed in serum-
free condition (FCS-0%). While acetylated [OTR4131] had low
significant effects on the migration of rMSC(−) (Fig. 3A) and
rMSC(+) (Fig. 3B), the sulfated compound [OTR4120] improved
rMSC(−) migration by 3.6 fold at 100 ng/mL as compared to
CT cells (Fig. 3A). This promoting effect was not significantly
reduced by the addition of SU5402, suggesting that it could
be due to interactions with HBP secreted by rMSC(−), other
than FGF-2. Moreover this stimulatory effect of [OTR4120] on
FGF-2 treated rMSC(+) was enhanced by 2.8 fold at
100 ng/mL as compared to CT cells (Fig. 3B) and partially
inhibited by the addition of SU5402, indicating that [OTR4120]
is able to interact at least with FGF-2, in addition to other
HBP, to induce cell migration.
Then, migrations were analyzed in FCS-2% condition. Both
GAG mimetics significantly induced rMSC(−) migration by 1.3folds at 100 ng/mL compared to CT FCS-2%(Fig. 3A), whereas
HS or heparin were less efficient at the same dose. The addi-
tion of GAG mimetics allowed to reach 45% of the migration
level obtained with positive control performed in FCS-20%.
This suggests that GAG mimetics interact with HBP, secreted
by cells or present in FCS-2%, to chemoattract rMSC(−). The
most significant migratory effect of the two GAG mimetics
was revealed on rMSC(+) (Fig. 3B, 2- and 2.4-fold increases
of cells/field). Under these conditions, GAG mimetics trig-
gered cell migration to a similar extent than HS and heparin,
corresponding to 75% of the migratory efficacy obtained with
FCS-20%. These data indicate that FGF-2 long term treat-
ment of rMSC(+) potentiates the stimulatory effect of GAG
mimetics. Such result is relevant since SU5402 addition abro-
gates these migratory effects. This could be due to a direct in-
teraction of the GAGmimetic with FGF-2/FGFR1 pathway or to
the ability of the FGF-2 treatment to modify the profile of che-
moattracting HBP secreted by rMSC(+).
Finally, we observed that the migratory effect of the
acetylated compound [OTR4131] is only revealed in the pres-
ence of FCS-2%, independently of FGF-2 long term treat-
ment. This suggests that acetyl groups in the sulfated
compound are able to drive some specificity against particu-
lar chemokine(s) present in FCS.
In addition, double labeled Annexine+/PI+apoptotic cells
were analyzed by flow cytometry on each condition, and
were less than 5% of total population (data not shown), sug-
gesting that rMSC were not subjected to apoptosis in the mi-
gration medium even at low FCS concentrations. Moreover,
this level of apoptotic cells remained the same regardless
of the concentration of GAG mimetics used, highlighting
that the migratory effects of GAG mimetics were not due
to protective effects against apoptosis.
Effects of FGF-2 and GAG on rMSC differentiation
The potential of rMSC(−) and rMSC(+) to undergo differentia-
tion was assessed by culturing cells in adipogenic and osteo-
genic induction media for 14 days. Adipogenic differentiation
was evaluated by Oil Red O specific staining of cytoplasmic
AB
Figure 2 Effect of GAG, natural and mimetics, on rMSC proliferation. P2 rMSC, amplified without (rMSC(−) panel A) or with 5 ng/mL
of FGF-2 (rMSC(+) panel B), were seeded at low density and treated with the indicated concentration of GAG mimetics [OTR4131],
[OTR4120], HS, Heparin or FGF-2 in FCS-2% supplemented media, in the presence of chemical inhibitor SU5402 (10 μM, hatched bar)
for 3 days. Cell numeration was performed by MTT assay. The proliferation rates of each condition were expressed as fold changes
as compared to control conditions (CT) from rMSC(−) (full line). Values are the mean and SEM calculated from triplicates in 3 inde-
pendent experiments, (n=9, *pb0.05; **pb0.01, ***pb0.001).
184 G. Frescaline et al.lipidic droplets (Fig. 4A) and intracellular triglyceride accumu-
lation quantification (Fig. 4B). Oil RedO stainingwere negative
in control (CT) conditions in rMSC(−) and rMSC(+) (Arbitrary
Unit (AU)=0), showing that FGF-2 treatment did not induce
lipid droplet accumulation. Addition of GAG mimetics to CT
conditions did not induce droplet accumulation either (data
not shown). When rMSC were induced to differentiate in adipo-
cytic medium (AD), staining intensities were significantly in-
creased. This effect was amplified for rMSC(+) (AU=0.5) as
compared to rMSC(−) (AU=0.2), suggesting that FGF-2 treat-
ment of rMSC potentiated their adipogenic differentiation.Furthermore, addition of GAG mimetics slightly decreased
lipid triglyceride accumulation in rMSC induced to differentiate
(Fig. 4A). However these decreases, measured by Oil Red O rel-
ative quantification, were not statistically significant (Fig. 4B).
This suggests that sulfated GAG mimetics do not have signifi-
cant effect on adipocytic differentiation of rMSC.
The effect of FGF-2 and/or GAG mimetics on osteogenic
phenotype of rMSC(−) and rMSC(+) was then evaluated in a
control medium (CT) and in osteogenic induction medium
(OS) after 14 days of culture. Von Kossa stainingwas performed
to visualize calcium deposit (Fig. 5A) and transcript levels of
AB
Figure 3 Effect of GAG, natural and mimetics, on rMSC migration capacity. After an overnight stimulation in migration medium
(MM) with FCS-0% or FCS-2%,, P2 rMSC(−) (panel A) and rMSC(+) (panel B), were seeded in upper Boyden chambers and exposed to
indicated concentrations of GAG mimetics or HS, Heparin (100 ng/ml) or FCS-20%, in the presence of chemical inhibitor SU5402
(10 μM, hatched bar), into lower chambers. Migrations were performed through transwell for 6 h and the migrated cells were
MGG-stained and counted. Data represent the mean and SEM from 3 independent experiments with each condition in duplicate. In
each MM, 0% or 2% FCS, effect of GAG was statistically compared to internal control (CT). (n=6, *pb0.05; **pb0.01, ***pb0.001).
185GAG mimetics potentiate the clonogenicity, proliferation migration and differentiation propertiesthe osteogenic genes, alkaline phosphatase ALP and RUNX2
transcription factor, were evaluated by qRT-PCR (Fig. 5B).
First we analyzed the effect of FGF-2 long term treatment on
the osteogenic phenotype: Von Kossa staining was stronger
for rMSC(−) than for rMSC(+) in OS medium (Fig. 5A). This cyto-
logical observation was confirmed by gene expression analysis,
since in CT condition, basal level of ALP and RUNX2 expression
were clearly down-regulated in rMSC(+) as compared to
rMSC(−). ALP and RUNX2 gene expression were induced signifi-
cantly for rMSC(−) and rMSC(+) in OS conditions as compared to
CT (Fig. 5B). These results suggest that FGF-2 treatment of
rMSC inhibits basal levels of osteogenic gene expression in CT
condition and subsequentmatrixmineralization but does not in-
hibit transcriptional activation of osteoblastic genes. Next, we
analyzed the effect of GAGmimetics on osteogenic differentia-
tion of fMSC. We did not observe any modification of Von Kossa
staining when the molecules were added to OS medium (data
not shown). However their addition to CT medium induced apositive Von Kossa staining of rMSC(−) and rMSC(+) (Fig. 5A).
These observations were confirmed by induction of osteogenic
gene expression levels (Fig. 5B): in CT condition, addition of
[OTR4120] significantly induced expression of ALP (1.7 fold for
rMSC(−), 1.6 fold for rMSC(+)) and RUNX2 (1.5 fold for
rMSC(−),1.9 fold for rMSC(+)). These data suggest that in the
absence of osteoinductive factors, GAG mimetic [OTR4120]
was able to inducemineralization and to initiate the osteogen-
ic transcription program of rMSC. In OS condition, addition of
the mimetics did not induce significant changes in ALP and
RUNX2 levels of expression in rMSC(−) and rMSC(+) cells, prob-
ably because these OS conditions overload the GAG mimetics
effects. Finally, even if [OTR4131] also seems to potentiate
mineralization and osteoblastic gene expression, this is only
significant for RUNX2 on rMSC(+), suggesting that, as observed
for migration properties, the modulatory effects of this acety-
lated GAGmimetic aremore restricted to specific HBP present
in the media. These results indicate that FGF-2 long term
AB
Figure 4 Effect of GAG mimetics on rMSC adipogenic differentiation. P2 rMSC(−) and rMSC(+) were differentiated in adipocytic in-
duction medium (AD) and compared to control medium (CT), without or with the mimetics [OTR4120] and [OTR4131] (100 ng/mL) for
14 days. (A) Cytological Oil Red O staining of lipid vesicles was performed at Day 14. (B) Intracellular triglyceride contents were quan-
tified after direct extraction by DMSO, relatively to absorbances at 510 nm. Backgrounds from CT samples were deduced. Values
expressed in arbitrary units (AU) are the mean and SEM calculated from 3 independent experiments with each condition tested in trip-
licates (n=9, **pb0.01).
186 G. Frescaline et al.treatment is inhibitory for osteogenic phenotype of rMSC
whereas GAG mimetics can differently potentiate this pheno-
type according to specific structural features.Discussion
Bone marrow MSC are currently exploited in clinical trials as
a promising cell therapeutic tool to repair damaged tissues.
During regenerative processes, the properties of MSC are
regulated through complex interactions between HBP and
GAG harboring fine specific chemical structures (Cool and
Nurcombe, 2005; Jackson et al., 2006). In the past few
years, structural and functional analogs of GAG were devel-
oped and demonstrated to display regenerative properties
as illustrated in animal model of bone repair (Lafont et al.,
2004). Here, we studied the effect of two structurally differ-
ent GAG mimetics, equally sulfated and bearing or not acetyl
groups, on the properties of MSC. We hypothesize that GAG
mimetics can represent potential therapeutic alternatives
to treatments with exogenous growth factors, since they
can modulate endogenous growth factor activities. The invitro effects of these GAGmimetics, with or without continuous
treatment with FGF-2, were studied on rMSC obtained after pu-
rification, amplification and functional characterization.Effects of FGF-2 treatment on MSC clonogenicity
and differentiations
In vitro studies have demonstrated the complexity of FGF-2
effects on osteoblastic cells in culture, since exogenous
treatments modulate positively or negatively both growth
and differentiation through separate pathways, each of
which requiring spatially and temporally controlled concen-
trations (Noff et al., 1989; Raucci et al., 2008; Quarto and
Longaker, 2008).
We demonstrate for the first time that the presence of
FGF-2 (5 ng/mL) at day 0 on rat MSC cultures from BMMC de-
creases the CFE of these cells. Phenotypic characterization
of the rMSC(−) and rMSC(+) populations suggest that in the
presence of FGF-2, some hematopoietic contaminating cells
remained despite homogeneous morphology and clear ex-
pression of mesenchymal markers. In previous works, FGF-2
AB
Figure 5 Effect of GAG mimetics on rMSC osteogenic differentiation. P2 rMSC(−) and rMSC(+) were differentiated in osteogenic in-
duction medium (OS) and compared to control basal medium (CT), without or with the mimetics [OTR4120] and [OTR4131] (100 ng/mL).
(A) Cytological Von Kossa staining of calcium deposits was performed at Day 14. (B) Phosphatase alkaline (ALP) and transcription fac-
tor (RUNX2) expression levels were analyzed by quantitative PCR. Values are the mean and SEM calculated from 3 independent ex-
periments with each condition tested in triplicates (n=9, *pb0.05; **pb0.01; ***pb0.001).
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um, to stimulate rapidly the capacity of the cells to produce
mineralized bone like tissue. However, no effect of FGF-2 was
observed, may be because the culture medium used allowed
the rapid selection of mesenchymal osteoprogenitor cells, lim-
iting the possibility of hematopoietic cell amplification (Kotev-
Emeth et al., 2000; Pitaru et al., 1993). Our present result
clearly indicates that, even if FGF-2 mitogenic activity is of in-
terest for MSC expansion, it must not be added from the begin-
ning of cultures in basal media, to avoid limited efficiency of
MSC colony formation and presence of contaminating cells.Moreover, our results show that long term treatment with
FGF-2 inhibits not only MSC clonogenicity but also calcium de-
position and osteogenic marker expression. Previous works
have described that FGF-2 regulatory activity on proliferation
and osteoblastic differentiation are tightly linked. In these
studies, exogenous FGF-2 up to 3 ng/mL, applied during rat
calvaria osteoblast or MSC growth phase only, was shown to
improve their growth and subsequent mineralization (Pitaru
et al., 1993; Hanada et al., 1997; Ling et al., 2006). However
these processes were inhibited at 10 ng/mL of FGF-2 (Noff et
al., 1989). Short term exposure of MSC to FGF-2, followed by
188 G. Frescaline et al.treatment with BMP-2, improved their osteogenic differentia-
tion (Hanada et al., 1997; Martin et al., 1997), whereas long
term exposure clearly inhibited maturity and mineralization,
(Chaudhary et al., 2004; Dombrowski et al., 2009). In accor-
dance with these reports, we confirm that a long term treat-
ment at dose 5 ng/mL is deleterious for proliferation of rat
MSC and mineralization during osteogenic differentiation.
Osteoblasts and adipocytes are both derived from mesen-
chymal marrow progenitors, according to lineage specific
differentiation, tightly controlled by intracellular signals
and extracellular factors. Among these, FGF-2 effect on adi-
pocytic differentiation is controversial. Indeed in vitro stud-
ies have suggested both pro- or anti-adipogenic effects of
FGF-2 after treatment of different cells lines or MSC cultures
(Neubauer et al., 2004; Navre and Ringold, 1989). However,
recent in vivo data obtained on fgf-2 null mice clearly sup-
port an anti-adipogenic effect of FGF-2 in bone, since
these mice present an increase of bone marrow fat as well
as induction of adipogenic differentiation pathway associat-
ed to inhibition of osteoformation (Xiao et al., 2010). On the
contrary, our in vitro results indicate that sustained treat-
ment with FGF-2 is necessary to optimize vesicle droplets
formation whereas it inhibits mineralization. This apparent
discrepancy points out differences classically observed be-
tween in vitro data from exogenous treatment as compared
to in vivo endogenous growth factor roles analysis. Such dis-
crepancy could be explained by availability of ECM com-
pounds such as GAG, which regulate growth factors in vivo.
Moreover, these data underline that, as previously described
for osteogenic differentiation, kinetics and doses of FGF-2
are also important for adipogenic differentiation. Modula-
tion of FGF-2 signaling by matrix components such as GAG,
may be a key element in determining the choice of MSC to
proliferate or to differentiate through adipogenic or osteo-
genic pathway.Chemically different GAG mimetics have distinct ef-
fects on clonogenicity and growth properties of rMSC
Although ubiquitous, GAG are characterized by their exten-
sive structural diversity based on the number and location
of sulfated groups (Merry and Gallagher, 2002; Handel et
al., 2005). The biological relevance of such sulfation pat-
terns of HS was demonstrated for their specific binding of
hematopoietic growth factor in the stromal bone marrow
niche (Gordon et al., 1987). These variable sulfation pat-
terns are crucial during bone development and regeneration
because of their abilities to interact with growth factors and
morphogens, such as FGF-2 and BMP, and then to modulate
cell proliferation and differentiation (Ling et al., 2006;
Habuchi et al., 2004). To date, other structural features of
GAG, such as the presence of partially acetylated regions,
have been considered of less biological relevance. However,
we recently demonstrated that whereas the two equally sul-
fated GAG mimetics [OTR4131] and [OTR4120] are able to mo-
bilize hematopoietic progenitors in vivo, only the acetylated
one [OTR4131], is able to mobilize a specific more immature
population of hematopoietic stem cells (HSC) (Albanese et
al., 2009). Given the relevance of the chemical structure
of GAG on their biological activities on stem cells, we tested
the effect of [OTR4131] and [OTR4120], on MSC.Our first results indicate that the treatment of BMMC with
GAG mimetics during the first step of rMSC cultures can in-
duce an increase of CFE, which is of interest for optimizing
the preparation of stem cell based therapeutic products.
However, this effect is variable according to biological sam-
ples, suggesting that adhesive mechanisms in which mi-
metics are involved in this clonogenic effect need to be
clarified. Moreover the participation of some contaminating
cells in these cultures should be addressed.
Concerning growth properties, we observed that only the
acetylated product [OTR4131] significantly potentiates the
growth of rMSC through FGF-2/FGFR1 pathway. Our data
points out the importance of the hydrophobic regions on
the modulation of HBP proliferative activities. This is a new
information since the most extensively studied aspect of
GAG structures and activities mainly focuses on the content
and positions of their sulfate moieties, as illustrated by the
involvement of HS 6-O- sulfation for the binding to FGF-2
and its FGF-R dimerization (Turnbull et al., 1992; Pye et
al., 1998). Our results suggest that the acetyl group involve-
ment in the HS/FGF/FGFR complex formation and its mito-
genic signaling effect should be studied in greater detail.Chemically different GAG mimetics have distinct ef-
fects on migration properties of rMSC
The acetyl groups are characteristic of chondroitin sulfates
(CS) and of poorly sulfated HS sequences (NA/NS sequences).
It was demonstrated that during the latter phases of osteo-
genesis, bone ECM undergoes change in its predominant pro-
teoglycan species from HS proteoglycan (HSPG) to CS
proteoglycan (CSPG). The latter are primarily secreted to
create stable tissue forms as they bind calcium, mineralize
and maintain tissue hydration. The growth-promoting ef-
fects of the HSPG thus give way to the increasing need for
the structural integrity of adult bone tissue that is supported
by the CSPG (Cool and Nurcombe, 2005; Nurcombe et al.,
2007). We hypothesize that participation of such kinds of
CS in the medullar niche has been underestimated as they
could also be involved in progenitors and stem cell recruit-
ment during homeostasis and regenerative process.
Here, we validate the relevance of acetyl groups on mi-
gration properties under specific conditions. We demon-
strate for the first time that both sulfated GAG mimetics
are able to potentiate the migration capacity of MSC, proba-
bly through their ability to modulate chemo-attractant mol-
ecules, such as FGF-2, expressed by rMSC or present in
serum, with different specificity according to the presence
or not of acetyl groups. In Contrast to hematopoietic stem
cells, the chemo-attraction process of MSC does not rely on
a specific couple of chemokines/receptor such as SDF-1/
CXCR-4 but rather on a wide range of poorly understood sig-
nals (Ponte et al., 2007; Stich et al., 2008). Few studies have
currently identified specific chemokines involved in MSC mi-
gration and no data are available demonstrating synergistic
migratory effects of natural GAG. Such migratory properties
were hypothesized for GAG mimetics to explain regenerative
properties of RGTA11 (without acetyl groups) during cranial
calvaria suture closure, through osteoblastic progenitors re-
cruitment from dura mater (Lafont et al., 2004). In addition,
we previously demonstrated that GAG mimetics induced
189GAG mimetics potentiate the clonogenicity, proliferation migration and differentiation propertiesmobilization of hematopoietic progenitors involved interac-
tions with SDF-1 (Albanese et al., 2009). Moreover, it was dem-
onstrated that while HS sulfation is a foremost requirement,
acetylation of saccharides of constant charge density increases
the binding of chemokines (Schenauer et al., 2007). This sup-
ports our hypothesis asserting that, because of its acetyl
groups [OTR4131] has more affinity than [OTR4120] for chemo-
attractant factors that remain to be identified. Altogether,
our results suggest that regenerative effect of GAG mimetics
could also be explained by their ability to induce migration of
circulating or resident stem cells on the injury site.Sulfated [OTR4120] GAG mimetic is able to potenti-
ate osteogenic differentiation of rMSC
In a previous study, we have demonstrated that a GAG mi-
metic, named RGTA11, was able to potentiate proliferation
of osteoblastic cells in vitro, and to accelerate bone regen-
erative closure in a rat model of calvaria defect (Blanquaert
et al., 1995). It was hypothesized that such molecules would
have been able to create a matrix microenvironment suit-
able to induce migration of osteoblastic progenitor cells
from dura mater proximal region. In this work, our results
strengthen this hypothesis since we show that sulfated
[OTR4120] GAG mimetic supports both chemo-attraction and
osteogenic differentiation. Interestingly, this molecule
does not have significant proliferative activity. [OTR4120]
was able to initiate osteogenic transcription program of
rMSC, in the absence of osteoinductive factors, and to in-
duce mineralization despite the inhibitory effect of FGF-2.
The signal effectors responsible for this mimetic induced dif-
ferentiating effect need to be identified, as was done for
natural HS. HS potentiated proliferation and osteogenic dif-
ferentiation of rMSC, such as bone nodule formation and
mineralization, through their ability to enhance endogenous
FGF-2/FGFR1 signaling and to promote the expression of
FGFR1 (Dombrowski et al., 2009). HS are also required for
BMP signaling supporting the idea that HS orchestrate the
transition between proliferation and differentiation (Khan
et al., 2008). However, HS saccharides can also have an in-
hibitory effect on the activity of osteoinductive factors. In-
deed, enzymatic depletion of HS and CS from MSC cell
surface liberated and increased the biological activity of
BMP2, bone nodule formation, calcium accumulation and os-
teoblast marker expressions (Manton et al., 2007). HS may
be able to induce such a shift between proliferation and dif-
ferentiation by increasing RUNX2, which supports previous
findings showing the importance of stage-specific HS pat-
terns in controlling cell phenotype (Jackson et al., 2007). It
would be then of interest to analyze the ability of GAG mi-
metics to enhance osteogenic factor activity, through
osteoblast-specific transcription factors such as RUNX2.
In summary, a growing number of studies suggest that
during their growth phase, MSC establish an appropriate mi-
croenvironment, in which GAG contribute to the optimiza-
tion of the subsequent differentiation process through their
specific interactions with HBP (Bi et al., 2006; Nurcombe
et al., 2007). Our results suggest that GAG mimetics modu-
late clonogenicity, proliferation, migration and/or osteo-
genic differentiation properties of MSC, with structural
implications of sulfate and acetyl groups. We propose thata synthetic GAG library with distinct lengths, charges and
conformations would allow the screening of optimal GAG
structures, with unique regulating activity according to a
specific partner. Application of this chemical design strategy
in regenerative medicine is in accordance with innovative
tissue engineering approaches, which focus on the in situ re-
cruitment of stem and progenitor cells to the defective sites
and their subsequent use for guided tissue repair. Therefore,
GAG mimetics would be of great interest as an alternative to
exogenous growth factor treatments: in addition to consti-
tute matrix scaffolds for a proper cell environment, GAG mi-
metics are able to potentiate promising therapeutic product
based on adult stem cells.Materials and methods
Materials
The GAG mimetics [OTR4120] and [OTR4131] were obtained
from OTR3 Inc. (Paris, France). These sulfated polysaccha-
ride derivatives of dextran T40 are composed of about
2500 glucosidic units linked by α1-6 bonds (Papy-Garcia et
al., 2005). They present the same degrees of substitution
for carboxymethyl and sulfate residues as heparan sulfate
(HS), and differ only by the presence of acetyl groups in
the [OTR4131] derivative. Heparin and HS used as natural
GAG control were cell culture grade. Heparin was extracted
from porcine intestinal mucosa (Sigma-Aldrich, H9399 lot
125K1400). HS was extracted from bovine kidney (Sigma-Al-
drich, H7640 lot 068K7002). Recombinant human FGF-2 was
prepared as described (Courty et al., 1991). The chemical in-
hibitor SU5402 was purchased from Calbiochem, used at
10 μM final concentration, and its vehicle DMSO was diluted
1:1000 for the control.Rat mesenchymal stem cell isolation, clonogenicity
and culture
rMSC were prepared from both femora and tibias of male Wis-
tar rats (7 weeks old, avg weight 220 g, Janvier, France) as
previously described (Rochefort et al., 2006). Bone Marrow
Mononuclear Cells (BMMC) were seeded at the density of
5×105 cells/cm², in complete medium (CM) comprising
αMEM, (Invitrogen), 20% fetal calf serum (FCS) (PAA Laborato-
ries, Austria), 1% antibiotic/antimycotic (ATB/ATM) solution
(PAA) at 37 °C and 5% CO2 in a humidified chamber. After
2 days, cultures were washed with PBS to remove non-
adherent hematopoietic cells and the medium changed.
Cells were fed every 2–3 days until day 10, when colonies
formed of more than 50 fibroblastic adherent cells, character-
istic of Colony Forming Unit-Fibroblastic (CFU-F), were scored
after May-Grünwald Giemsa (MGG) staining. The Colony Form-
ing Efficiency (CFE) was calculated as the number of CFU-F per
106 BMMC seeded (Passage 0). Then amplification steps were
performed until sub-confluency, from CFU-F obtained in CM
supplemented or not with FGF-2 (5 ng/mL): cells named
rMSC(+) or rMSC(−) respectively were trypsinized, seeded at
104 cells/cm² density and passaged in CM(+) or CM(−). Media
were changed twice a week.
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Cells were trypsinized, washed in PBS 1x, blocked in PBS 1x
with 1% bovine serum albumin (BSA) (Sigma-Aldrich) and
stainedwithmouse anti rat monoclonal antibodies (Ab) direct-
ed against CD31, CD44 CD45, CD54, CD90 (Abd Serotec, Düssel-
dorf, Germany) and CD73 (BD Pharmingen, San Diego, CA,
USA), as described [28]. Secondary labeling was performed
with a FluoProbes 488 donkey anti mouse IgG (Interchim,
France). Cells stained with irrelevant isotype Ab (Abd Serotec)
were analyzed in parallel as negative controls. Cell labeling
was analyzed on 10 000 events at least with a MACS Quant cyt-
ometer (Miltenyi Biotec, Bergisch Gladbach, Germany).
Proliferation assay
Passage 2 rMSC(−) and rMSC(+) cells were seeded in 24-well
culture plates at the density of 103 cells/well and allowed to
adhere overnight. Cells were then washed and treated with
varying concentration of GAG or FGF-2 or chemical inhibitor
in medium containing 2% FCS (CT). After 72 h, the total num-
ber of viable cells was estimated with the colorimetric MTT
cell viability assay, as compared to a standard curve, accord-
ing to the manufacturer's protocol (Sigma-Aldrich).
Cellular migration in Boyden's chamber assay
Migration assays were performed in 24-well micro-chemotaxis
chambers (Corning Costar, USA) using polycarbonate mem-
branes with 8-μm pores as described previously (Ponte et al.,
2007; Rochefort et al., 2006). Briefly, 250×103 P2 rMSC(+)
and rMSC(−) cells were harvested in 0.1 mL of migration medi-
um (MM) composed of RPMI 1640 (Invitrogen), 0.25% BSA (Frac-
tion V, Sigma-Aldrich), FCS 0% or FCS 2%, then seeded in the
top chamber. The bottom chamber unit contained 0.6 mL of
MM supplemented or not with varying concentrations of
GAGs. MM without any factor or supplemented with 20% FCS
were used as negative or positive controls respectively. The
plates were incubated for 6 h at 37 °C. Then, all membranes
were MGG-stained, mounted and photographed. Quantitation
of migrated cells through filter was estimated on 3 separate
areas.
In vitro adipogenic and osteogenic differentiation
assays
Adipogenic and osteoblastic differentiations were initiated
in 6-well culture on P2 rMSC(−) and rMSC(+) populations re-
spectively at 90% and 60% confluency. Adipogenic medium
was αMEM supplemented with 10% FCS, 100 μM isobutyl
methylxanthine, 60 μM indomethacin, 1 μg/mL insulin and
0.5 μM hydrocortisone. Osteogenic medium was αMEM sup-
plemented with 20% FCS, 0.1 μM dexamethasone, 2 mM β-
glycerophosphate and 150 μM ascorbic acid. All reagents
were supplied by Sigma-Aldrich. Corresponding control of
rMSC(−) and rMSC(+) were cultured with CM. All media, sup-
plemented or not with GAG mimetics, were changed twice a
week for 2 weeks. Oil Red-O staining was performed to re-
veal the intracellular triglyceride accumulation, which
were extracted by DMSO treatment (250 μL per well).Thereafter absorbance was measured at 510 nm and OD
values were used as arbitrary units (AU) to perform relative
quantification of differentiation level as compared to CT
cells. Von Kossa staining was performed to reveal calcium
deposit with silver nitrate solution 2% (w/v) (Sigma-Aldrich)
under a 60 watt light bulb for 1 h. The unreacted silver salt
was removed with sodium thiosulfate 2.5% (w/v) (Sigma-
Aldrich).
RNA extraction, reverse transcription and quantita-
tive polymerase chain reaction
RNA was extracted with TRIzol® reagent (Invitrogen, France),
DNase treatment was performed with a DNA-free Kit (Applied
Biosystems/Ambion, USA) and cDNAwere synthesized by Super-
script II Reverse Transcriptase (Invitrogen), according to the
manufacturer's protocol. Primers were designed by Primer3out-
put software (Rozen and Skaletsky, 2000), and obtained by
Eurofins MWG (Germany). The following specific oligonucleo-
tide primers were used: GlycerAldehyde-3-Phosphate DeHydro-
genase (GAPDH, NM_017008, forward 5′-TGC CAC TCA GAA GAC
TGT GG-3′, reverse 5′-GGA TGC AGG GAT GAT GTT CT-3′), Tu-
bulin alpha 1A (Tub1A, NM_022298.1, forward 5′-GCA CTC
TGA TTG TGC CTT CA-3′, reverse 5′-GAG GGA AGC AGT GAT
GGA AG-3′), runt-related transcription factor 2 (RUNX2,
NM_053470, forward 5′-GCC GGG AAT GAT GAG AAC TA-3′, re-
verse 5′-GGA CCG TCC ACT GTC ACT TT-3′), and alkaline phos-
phatase (ALP, NM_013059, forward 5′-GAC AAG AAG CCC TTC
ACA GC-3′, reverse 5′-CTG GGC CTG GTA GTT GTT GT-3′). For
the real-time PCR, the amplifications were performed on the
LightCycler (Software version 3.5;) LightCycler FastSart DNA
Master SYBR Green I (Roche, Switzerland) following the manu-
facturer's procedure. All samples were amplified simultaneous-
ly in one assay run. Cycling conditions included one cycle of
8 min at 94°C followed by 48 cycles consisting of denaturation
for 15 s at 94°C, annealing for 25 s at respective Tm (65 °C
for GAPDH, Tub1A and RUNX2; 68 °C for ALP) and elongation
for 30 s at 72°C, in 2 mMMgCl2. After the final cycle themelting
curve was started for 10 s at 95°C, 30 s at 65°C and then tem-
perature was raised to 95°C (0.1°C/s). Relative quantification
of gene expression was performed using the comparative CT
method, also referred to as the ΔΔCT method. Two reference
genes, GAPDH and Tub1A were used as an endogenous control.
The normalization of these genes was accomplished with the
geNorm program (Vandesompele et al., 2002).
Statistical analysis
Results were expressed as mean of values±standard error
mean (SEM) from at least three independent experiments
with triplicate values per condition. Statistical analyses
were performed using Student's t-test (unpaired two-tailed).
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